2Dredge K, Marriott JB, Tedryk SM, et al. Protective antltum or immuneity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccineaiton is mediated by increased Th-1 type immuneity [J].Immunol, 2002,168 (10) :4914.
3Bom BG, Canetti C, Rocha FAC,et al. Tumoumecrosis factor-a mediates neutrophil migration to the knee synodal cavity during immune inflammation[J]. Eur J Phar, 2004, 496(7) : 197-204.
4Ziche M, Donnini S, Morbidelle L. Development of new drugs in angiogenesis[ J]. Curr Drug Targets, 2004,5(6) : 485-493.
5Anargyrou K,Dimopoulos MA, Sezer O, et al. Novel anti-myeloma agents and angiogenesis [J]. Leuk Lymphoma, 2008,49 ( 4 ) : 677- 689.
6Haslett PA, Roche P, Buflln CR, et al. Effective treatment of crythema nodosum leprosum with thalidomide is associated with immune stimulation[J]. J Infect Dis, 2005, 192(12) :2045-2053.
7Rajkumar SV, Rosiol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexarnethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma[J]. J Clin Oncol,2008,26(13) :2171- 2177.
8Rajkumar SV, Getz MA, Lacy MQ, et al. Thalidomide as initial theropy for early stage myeloma [J]. Leukemia, 2003,17 (4) : 775- 779.
9Tsubokura M, Kami M. Treatment for elderly patients with multiple myeloma[ J]. Lancet,2008, 371 (9617) :983.
10Verma A, List A F. Cytokine targets in the treatment of myelodysplastic syndromes[ J]. CurrHematol Rep, 2005,4(6) : 429-435.
9Rajkumar SV,Kyle RA.Angiogenesis in multiple myelon.Semin Oncol,2001,28(6):560-64.
10Ba ZR,Walker E,Karam MA,et al.Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple-myeloma:safety and efficacy.Ann Oncol,2006,17(12):1766-1771.
